arrow
M

Matthias Theobald

hematology and medical oncology
H指数:43
被引数:8,199

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland

德国和瑞士常规环境中,Brexucabtagene-autoleucel治疗复发/难治性套细胞淋巴瘤患者的疗效结果

2026-01-160
OAAI
Inflammatory stromal and T cells mediate human bone marrow niche remodeling in clonal hematopoiesis and myelodysplasia

炎症性基质细胞和T细胞介导克隆性造血和骨髓增生异常综合征中的人类骨髓微环境重塑

2025-11-180
OAAI
DISRUPTED HARMONY: IFN-RESPONSIVE T CELLS AND INFLAMMATORY MSCS RESHAPE THE BONE MARROW NICHE IN CHIP AND MDS THE TITO BASTIANELLO AND MDSF YOUNG INVESTIGATORS AWARDS

失调的和谐:IFN应答性T细胞和炎性MSCs重塑CHIP和MDS中的骨髓微环境——Tito Bastianello和MDSF青年 investigator 奖

2025-09-010
PRE
CRISPR-Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma

CRISPR-Cas9 TCR-Edited NKp30 CAR T细胞对表达B7H6的急性白血病和黑色素瘤表现出更优的抗肿瘤免疫活性。

2025-08-250
PRE
Case Report: Late-onset primary hemophagocytic lymphohistiocytosis leading to the diagnosis of Griscelli syndrome type 2 in a young woman with phenotypically inapparent partial albinism

病例报告:一例年轻女性因迟发性原发性噬血细胞性淋巴组织细胞增多症,继而导致Griscelli综合征2型的诊断,该患者具有表型不明显的部分白化病。

2025-08-070
OA
Synergistic Efficacy of Dual Menin and PRMT5 Targeting Against NPM1 mutated and KMT2A- rearranged Leukemia

双Menin和PRMT5靶向治疗NPM1突变型和KMT2A重排型白血病的协同疗效

BLOOD
IF23.1
2024-11-050
PRE
Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation

急性对BET抑制剂的耐药性通过p300协同激活重塑补偿性转录程序

BLOOD
IF23.1
2024-11-050
PRE
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome

靶向小胶质细胞中tgf β 活化激酶-1活化可降低CAR T免疫效应细胞相关神经毒性综合征

2024-05-133
PRE
Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax
2023-04-2722
OAAI
Profile of the multicenter cohort of the German Cancer Consortium's Clinical Communication Platform

德国癌症联盟临床交流平台多中心队列的概况

2023-04-051
OAAI